Takeda Pharmaceutical (TAK) Competitors

Takeda Pharmaceutical logo
$21.76 +0.35 (+1.63%)
Closing price 03:59 PM Eastern
Extended Trading
$21.82 +0.06 (+0.29%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TAK vs. NVO, PFE, BMY, SNY, and GSK

Should you buy Takeda Pharmaceutical stock or one of its competitors? Takeda Pharmaceutical's main competitors and comparable companies include Novo Nordisk A/S (NVO), Pfizer (PFE), Bristol Myers Squibb (BMY), Sanofi (SNY), and GSK (GSK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$46.80B3.71$15.51B$3.979.80
Takeda Pharmaceutical$28.32B2.43-$1.01B$0.7628.23

Novo Nordisk A/S has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 33.99% compared to Takeda Pharmaceutical's net margin of 8.26%. Novo Nordisk A/S's return on equity of 53.52% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S33.99% 53.52% 19.49%
Takeda Pharmaceutical 8.26%11.51%5.59%

In the previous week, Novo Nordisk A/S had 29 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 32 mentions for Novo Nordisk A/S and 3 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.38 beat Takeda Pharmaceutical's score of 0.20 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
13 Very Positive mention(s)
5 Positive mention(s)
6 Neutral mention(s)
4 Negative mention(s)
4 Very Negative mention(s)
Neutral
Takeda Pharmaceutical
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.1%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.2%. Novo Nordisk A/S pays out 20.7% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 63.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S presently has a consensus target price of $59.44, indicating a potential upside of 52.84%. Given Novo Nordisk A/S's higher possible upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
5 Sell rating(s)
16 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.00
Takeda Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Pfizer?

Takeda Pharmaceutical (NYSE:TAK) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Takeda Pharmaceutical has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.2%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.2%. Takeda Pharmaceutical pays out 63.2% of its earnings in the form of a dividend. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer has a consensus price target of $30.32, suggesting a potential upside of 9.98%. Given Pfizer's higher possible upside, analysts clearly believe Pfizer is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00
Pfizer
2 Sell rating(s)
14 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.18

Pfizer has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$28.32B2.43-$1.01B$0.7628.23
Pfizer$62.58B2.51$7.77B$0.7039.38

Takeda Pharmaceutical has a net margin of 8.26% compared to Pfizer's net margin of 6.34%. Pfizer's return on equity of 19.88% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical8.26% 11.51% 5.59%
Pfizer 6.34%19.88%8.52%

In the previous week, Pfizer had 43 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 46 mentions for Pfizer and 3 mentions for Takeda Pharmaceutical. Pfizer's average media sentiment score of 0.35 beat Takeda Pharmaceutical's score of 0.20 indicating that Pfizer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pfizer
14 Very Positive mention(s)
10 Positive mention(s)
15 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Neutral

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Pfizer beats Takeda Pharmaceutical on 14 of the 20 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Takeda Pharmaceutical (NYSE:TAK) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Takeda Pharmaceutical has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Bristol Myers Squibb has higher revenue and earnings than Takeda Pharmaceutical. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$28.32B2.43-$1.01B$0.7628.23
Bristol Myers Squibb$48.19B2.47$7.05B$4.5112.93

Bristol Myers Squibb has a net margin of 18.47% compared to Takeda Pharmaceutical's net margin of 8.26%. Bristol Myers Squibb's return on equity of 60.48% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical8.26% 11.51% 5.59%
Bristol Myers Squibb 18.47%60.48%14.45%

In the previous week, Bristol Myers Squibb had 42 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 45 mentions for Bristol Myers Squibb and 3 mentions for Takeda Pharmaceutical. Bristol Myers Squibb's average media sentiment score of 0.26 beat Takeda Pharmaceutical's score of 0.20 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bristol Myers Squibb
11 Very Positive mention(s)
8 Positive mention(s)
10 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bristol Myers Squibb has a consensus target price of $65.46, suggesting a potential upside of 12.23%. Given Bristol Myers Squibb's higher probable upside, analysts clearly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00
Bristol Myers Squibb
1 Sell rating(s)
16 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.47

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.2%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.3%. Takeda Pharmaceutical pays out 63.2% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 55.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has raised its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Bristol Myers Squibb beats Takeda Pharmaceutical on 18 of the 20 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Sanofi?

Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Sanofi has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B2.26$8.84B$2.0222.80
Takeda Pharmaceutical$28.32B2.43-$1.01B$0.7628.23

Sanofi presently has a consensus price target of $53.00, suggesting a potential upside of 15.07%. Given Sanofi's higher probable upside, equities analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48
Takeda Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

Sanofi has a net margin of 8.70% compared to Takeda Pharmaceutical's net margin of 8.26%. Sanofi's return on equity of 15.16% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.70% 15.16% 8.48%
Takeda Pharmaceutical 8.26%11.51%5.59%

In the previous week, Sanofi had 16 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 19 mentions for Sanofi and 3 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.51 beat Takeda Pharmaceutical's score of 0.20 indicating that Sanofi is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
6 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Takeda Pharmaceutical
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.8%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.2%. Sanofi pays out 87.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Takeda Pharmaceutical pays out 63.2% of its earnings in the form of a dividend.

Summary

Sanofi beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to GSK?

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.7%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.2%. GSK pays out 61.8% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 63.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

GSK currently has a consensus target price of $56.30, suggesting a potential upside of 17.65%. Given GSK's higher possible upside, equities research analysts plainly believe GSK is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
3 Sell rating(s)
13 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.00
Takeda Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$43.07B2.25$7.54B$2.8816.62
Takeda Pharmaceutical$28.32B2.43-$1.01B$0.7628.23

15.7% of GSK shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, GSK had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for GSK and 3 mentions for Takeda Pharmaceutical. GSK's average media sentiment score of 0.35 beat Takeda Pharmaceutical's score of 0.20 indicating that GSK is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Takeda Pharmaceutical
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

GSK has a net margin of 13.00% compared to Takeda Pharmaceutical's net margin of 8.26%. GSK's return on equity of 41.41% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK13.00% 41.41% 11.09%
Takeda Pharmaceutical 8.26%11.51%5.59%

Summary

GSK beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TAK vs. The Competition

MetricTakeda PharmaceuticalPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$69.18B$13.61B$7.77B$21.76B
Dividend Yield2.23%2.58%2.47%3.83%
P/E Ratio12.3425.9631.9823.90
Price / Sales2.466.788.103.50
Price / Cash6.9615.6321.0115.54
Price / Book1.495.164.263.45
Net Income-$1.01B$2.86B$3.50B$1.07B
7 Day Performance1.53%-7.23%-7.93%-7.11%
1 Month Performance8.39%-9.61%-10.46%-7.16%
1 Year Performance54.60%-8.11%-2.79%2.58%

Takeda Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TAK
Takeda Pharmaceutical
2.5315 of 5 stars
$21.76
+1.6%
N/A+52.2%$69.18B$28.32B12.3447,000
NVO
Novo Nordisk A/S
3.8627 of 5 stars
$41.60
-0.1%
$59.44
+42.9%
-20.7%$181.50B$46.80B10.4569,505
PFE
Pfizer
3.5701 of 5 stars
$28.84
-0.2%
$30.32
+5.1%
+10.6%$164.33B$62.58B9.4575,000
BMY
Bristol Myers Squibb
4.841 of 5 stars
$62.96
-0.7%
$65.46
+4.0%
+27.4%$127.39B$48.19B10.0032,500
SNY
Sanofi
3.9375 of 5 stars
$48.39
+0.0%
$53.00
+9.5%
-7.0%$117.49B$49.35B23.9674,846

Related Companies and Tools


This page (NYSE:TAK) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners